Your search history is turned on.
Date: April 16, 2024 Jurisdictions: Alberta, British Columbia, Ontario
St. Michaels Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, April 16, 2024 -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michaels Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the preventio...
Date: April 3, 2024 Jurisdictions: Alberta, British Columbia, Ontario
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, April 03, 2024 -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pain Management at the University Health Network (UHN), h...
Date: April 2, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, April 02, 2024 -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and trea...
Date: March 18, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2 British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virus Phas...
Date: March 15, 2024 Jurisdictions: Alberta, British Columbia, Ontario
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, March 15, 2024 -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgarys Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the prevention ...
Date: March 7, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, March 07, 2024 -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treat...
Date: March 6, 2024 Jurisdictions: Alberta, British Columbia, Ontario
ARCH BIOPARTNERS INC. (the "Corporation") Annual and Special Meeting April 2, 2024 at 11:00 AM (Canada/Eastern Standard) 545 King St W, Toronto, Ontario M5V 1M1 (the "Meeting") Proxy Voting Guidelines and Conditions THIS PROXY IS SOLICITED BY OR ON BEHALF OF THE MANAGEMENT OF THE CORPORATION. THIS PROXY SHOULD BE READ IN CONJUNCTION WITH THE MEE...
_ 1 ARCH BIOPARTNERS INC. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General and Special meeting of shareholders (the Meeting) of Arch Biopartners Inc. (the Corporation) will be held at the Corporations head office located at 545 King Street West, Toronto, Ontario, Canada o...
_.pdf ...
Date: February 29, 2024 Jurisdictions: Alberta, British Columbia, Ontario
PRESS RELEASE - FOR IMMEDIATE DISTRIBUTION January 10, 2024 Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury Toronto, Canada - Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announc...